Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Dean Vayser

Podiatrist Carlsbad, CA Doctor of Podiatric Medicine

NPI 1013961598 CMS profile 227895

6260 El Camino Real, Fl 1, Carlsbad, CA 92009

Open in the dashboard

General payments

$23,531

68 records reported · program years 2019–2025

Research payments

$242,396

Paid to them · 27 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,190,189 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Dean Vayser of Carlsbad, CA is reported in the CMS Open Payments database as having received $23,531 across 68 general payments and $242,396 in research payments paid to them. Separately, studies naming them as principal investigator received $1,190,189 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $172 2
2024 General $154 1
2024 Research $1,759 3
2023 General $2,043 5
2022 General $18,493 12
2021 General $378 7
2021 Research $8,500 4
2020 General $814 7
2020 Research $222,137 18
2019 General $1,477 34
2019 Research $10,000 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dean Vayser
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Dean Vayser were reported at $172. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Dean Vayser Podiatrist median Middle half National median
2019 $1,477 $196 $72–$601 $163
2020 $814 $118 $38–$335 $114
2021 $378 $169 $57–$573 $132
2022 $18,493 $220 $74–$782 $149
2023 $2,043 $208 $71–$635 $160
2024 $154 $237 $87–$681 $164
2025 $172 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Hartmann USA, Inc. $17,612 6 payments
  2. ConvaTec Inc. $2,646 12 payments
  3. KCI USA, Inc $595 4 payments
  4. TissueTech, Inc. $558 3 payments
  5. Organogenesis Inc. $489 16 payments
  6. Acera Surgical, Inc. $469 6 payments
  7. Musculoskeletal Transplant Foundation Inc. $256 1 payment
  8. Integra LifeSciences Corporation $239 7 payments
  9. Solventum Corporation $150 1 payment
  10. Genzyme Corporation $120 1 payment
  11. Other $397 11 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $17,825 3 payments
  2. Food and Beverage $2,865 60 payments
  3. Travel and Lodging $2,840 5 payments
Products named General payments · program years 2019–2025
  1. Zetuvit Plus $17,577 5 payments
  2. INNOVAMATRIX AC $1,926 3 payments
  3. Prokera $558 3 payments
  4. AmnioGraft $558 3 payments
  5. AmnioGuard $558 3 payments
  6. Apligraf $456 13 payments
  7. Restrata Wound Matrix $455 5 payments
  8. CONVATEC INC. $325 1 payment
  9. AQUACEL AG+ $200 2 payments
  10. Integra $162 2 payments
  11. Other $2,159 63 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. PolarityTE, Inc. $147,000 15 payments
  2. Integra LifeSciences Corporation $93,637 9 payments
  3. Lexicon Pharmaceuticals, Inc. $1,759 3 payments

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

33

Median for Podiatry: 160

Drug cost

$4,427

Median for Podiatry: $2,368

Branded share of claims

48.5%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Santyl Collagenase Clostridium Hist. Brand 16 $4,278
Doxycycline Hyclate Generic 17 $149

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$82,854

Of which drugs: $133

Medicare patients

432

Average age 76

Services billed

1,163

226 women, 206 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 66%
Arthritis 48%
Ischemic heart disease 31%
Diabetes 28%
Osteoporosis 25%
Atrial fibrillation 22%
Depression 22%
Chronic kidney disease 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 37 168 $124

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

95 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record